Syed Kazmi is the Executive Director of Business Development for Amgen based in Thousand Oaks, California. In this role, Syed focuses on corporate mergers and acquisitions, global licensing and strategic collaborations in key therapeutic areas and serves as the Head of International Business Development for Amgen. He led the acquisition of Onyx Pharmaceuticals by Amgen for over $10B in 2013, executed multiple global oncology licensing transactions and led regional strategic distribution deals in emerging markets.
Prior to joining Amgen in 2012, Syed served as Vice President, Business Development & Strategic Planning at Ligand Pharmaceuticals for five years. From 1995- 2007, he held various positions at Ligand, including Senior Director of Business Development, Leader of multiple drug development teams, Director of Project Management and Senior Scientist in Molecular Endocrinology.
Prior to joining Ligand, Syed worked in discovery research at Johnson & Johnson from 1988 to 1995, where his most recent position was Principal Scientist in endocrinology and inflammation drug development programs. From 1985 to 1988, he held his postdoctoral research positions at McMaster University, Hamilton. Syed received a Ph.D. in biochemistry from J.N. University, New Delhi, and an executive MBA from San Diego State University
IFAPP Academy provides an online, continuing professional development course, Medical Affairs in Medicines Development, resulting in the Professional Certification, Certified Medicines Development (CMD).